

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1>  <i>(Use as many sheets as necessary)</i>				<i><b>Complete if Known</b></i>	
				Application Number	10/625,202
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. G. Hill
Sheet	1	of	3	Attorney Docket Number	ALXN-P02-089

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		
	BA	WO-95/032734	12-07-1995	Innogenetics NV	
	BB	WO-00/63251	10-26-2000	Univ Nijmegen et al.	
	BC	WO-02/50119-A2	06-27-2002	Stichting Katholieke Universiteit	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/625,202
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. G. Hill
Sheet	2	of	3	Attorney Docket Number	ALXN-P02-089

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CF1	Bakker et al., "Melanocyte Lineage-specific Antigen gp100 Is Recognized by Melanoma-derived Tumor-infiltrating Lymphocytes," J. Exp. Med., 179:1005-1009 (1994).	
	CG1	Fè d'Ostiani, C., et al., "Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus <i>Candida albicans</i> : Implications for Initiation of T Helper Cell Immunity In Vitro and In Vivo," J. Exp. Med., 191(10):1661-1673 (2000).	
	CH1	Forsyth, C. B., et al., "Interaction of the Fungal Pathogen <i>Candida albicans</i> with Integrin CD11b/CD18: Recognition by the I Domain Is Modulated by the Lectin-Like Domain and the CD18 Subunit," The Journal of Immunology, 161:6198-6205 (1998).	
	CI1	Hong et al., "Human Immunodeficiency Virus Envelope (gp120) Binding to Dc-SIGN and Primary Dendritic Cells is Carbohydrate Dependent but Does not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding," <u>Journal of Virology</u> , 12855-12865 (2002).	
	CJ1	Jameson et al., "Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques," <u>Journal of Virology</u> , 76:1866-1875 (2002).	
	CK1	Marth, T., et al., "Regulation of Interleukin-12 by Complement Receptor 3 Signaling," The Journal of Experimental Medicine, 185(11):1987-1995 (1997).	
	CL1	Mitchell et al., "A Novel Mechanism of Carbohydrate Recognition by the C-type Lectins DC-SIGN and DC-SIGNR," <u>The Journal of Biological Chemistry</u> , 276:28939-28945 (2001).	
	CM1	Netea, M. G., et al., "Immune sensing of <i>Candida albicans</i> requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors," The Journal of Clinical Investigation, 116(6):1642-1650 (2006).	
	CN1	Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CO1	Rosati et al., Cytokine Response to Inactivated <i>Candida albicans</i> in Mice. Cell. Immunol., 162:256-264 (1995)	
	CP1	Soilleux, E.J., et al., "Cutting Edge: DC-SIGN; a Related Gene, DC-SIGNR; and CD23 Form a Cluster on 19p.13, <sup>1,2</sup> ," The Journal of Immunology, 165:2937-2942 (2000).	
	CQ1	Szabo, I., et al., "Modulation of Macrophage Phagocytic Activity by Cell Wall Components of <i>Candida albicans</i> ," Cellular Immunology, 164:182-188 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/625,202
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. G. Hill
Sheet	3	of	3	Attorney Docket Number	ALXN-P02-089

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CR1	Vazeux et al., "Cloning and Characterization of a New Intercellular Adhesion Molecule ICAM-R," <u>Nature</u> , 360:485-488.	
	CS1	Wu et al., "Functional Evaluation of DC-SIGN Monoclonal Antibodies Reveals DC-SIGN Interactions with ICAM-3 Do Not Promote Human Immunodeficiency Virus Type I Transmission," <u>J. Virol.</u> , 76(12):5905-5914 (2002).	
	CT1	Human CD209: anti-Human CD209 (DC-SIGN) antibody, eBioscience, <a href="http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm">http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm</a> , 1/5/2004.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.